Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis o... by Kei Sonehara, Kazunari Tateishi, Kiyotaka Yoh, Kazuhiro Usui, Yukio Hosomi, Kazuma Kishi, Go Naka, Kageaki Watanabe, Shu Tamano, Kohei Uemura, Hideo Kunitoh

Get full text

Corrigendum to ‘Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC’ [JTO Clinical and Research Reports, Volu... by Tsuyoshi Hirata, MD, Yuji Uehara, MD, Taiki Hakozaki, MD, Takayuki Kobayashi, MD, Yuto Terashima, MD, Kageaki Watanabe, MD, Makiko Yomota, MD, PhD, Yukio Hosomi, MD, PhD

Get full text